Royce & Associates’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,897
| Closed | -$310K | – | 837 |
|
|
2024
Q4 | $310K | Sell |
2,897
-3,193
| -52% | -$342K | ﹤0.01% | 788 |
|
|
2024
Q3 | $610K | Sell |
6,090
-4,996
| -45% | -$500K | 0.01% | 781 |
|
|
2024
Q2 | $934K | Sell |
11,086
-4,038
| -27% | -$340K | 0.01% | 724 |
|
|
2024
Q1 | $1.11M | Sell |
15,124
-5,037
| -25% | -$368K | 0.01% | 713 |
|
|
2023
Q4 | $1.44M | Buy |
20,161
+7,450
| +59% | +$532K | 0.01% | 694 |
|
|
2023
Q3 | $762K | Buy |
12,711
+6,325
| +99% | +$379K | 0.01% | 772 |
|
|
2023
Q2 | $460K | Buy |
+6,386
| New | +$460K | ﹤0.01% | 847 |
|
|
2020
Q1 | – | Sell |
-721
| Closed | -$47K | – | 1175 |
|
|
2019
Q4 | $47K | Sell |
721
-206
| -22% | -$13.4K | ﹤0.01% | 1046 |
|
|
2019
Q3 | $58K | Buy |
927
+414
| +81% | +$25.9K | ﹤0.01% | 1036 |
|
|
2019
Q2 | $37K | Buy |
513
+32
| +7% | +$2.31K | ﹤0.01% | 1059 |
|
|
2019
Q1 | $38K | Sell |
481
-18,755
| -97% | -$1.48M | ﹤0.01% | 1063 |
|
|
2018
Q4 | $1.63M | Buy |
+19,236
| New | +$1.63M | 0.01% | 785 |
|
|
2018
Q1 | – | Sell |
-112
| Closed | -$10K | – | 1267 |
|
|
2017
Q4 | $10K | Buy |
112
+13
| +13% | +$1.16K | ﹤0.01% | 1175 |
|
|
2017
Q3 | $8K | Buy |
+99
| New | +$8K | ﹤0.01% | 1189 |
|